Showing results (531-540 of 585) with videos related to

Sort By:
Pageof 59
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 29, 2024
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapyYuki Tahata, Hayato Hikita, Satoshi Mochida, et al.
Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Scientific Reports|January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinibHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Plos One|February 13, 2014
New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in AsiaNao Nishida, Hiromi Sawai, Koichi Kashiwase, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Gastroenterology|February 7, 2017
Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus InfectionKentaro Matsuura, Hiromi Sawai, Kazuho Ikeo, et al.
Cancer Medicine|November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approachTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Pageof 59